C
CRGX
vs
S&P 500
S&P 500
Over the past 12 months, CRGX has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's +14% growth.
Stocks Performance
CRGX vs S&P 500
Performance Gap
CRGX vs S&P 500
Performance By Year
CRGX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CARGO Therapeutics Inc
Glance View
CARGO Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 74 full-time employees. The company went IPO on 2023-11-10. CARGO Therapeutics, Inc. is a clinical-stage biotechnology company. The firm is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company’s lead program, CRG-022, is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate. The firm is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The firm is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.
